Sep 07, 2023 / 12:30PM GMT
Operator
Good morning, everyone. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Conference Call. (Operator Instructions). It is now my pleasure to turn the call over to Zack Kubow of Real Chemistry. Please go ahead, sir.
Zack Kubow - Real Chemistry, Inc. - Group Director
Thank you, operator, and good morning, everyone. Thanks for joining us for the Corvus Pharmaceuticals, soquelitinib FDA meeting of Phase III clinical trial update conference call. On the call are Richard Miller, Chief Executive Officer; and Leiv Lea, Chief Financial Officer. The executive team will open the call with some prepared remarks followed by a question-and-answer period.
I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties
Corvus Pharmaceuticals Inc Soquelitinib Phase 3 Clinical Trial Plan and Business Update Conference Call Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers